mortality/aging
| N |
• when pregnant mice are maintained on 10 ug/ml or higher doxycycline, double-transgenic mice with normal morphology are born at expected ratios
|
|
• 1-5 ug/ml doxycycline treatment during gestation allows full-term development of double-transgenic mice, but pups are born dead or die shortly after birth
|
|
• no live animals are obtained in litters born when the pregnant mouse does not receive doxycycline during gestation
|
growth/size/body
|
• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation are runted
|
immune system
|
• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
|
dermatitis
(
J:70670
)
|
• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time
|
cellular
|
• cell proliferation in the epidermis is significantly reduced in double transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation
|
integument
|
• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
• with reintroduction of doxycycline at >5 ug/ml in diet, nearly complete hair regrowth is observed within 14 days
|
|
• weanlings treated by doxycycline withdrawal display progressive hair loss
|
|
• in weanlings treated by doxycycline withdrawal, many hair follicles appear hyperplastic with abnormal morphologies
|
|
• hair follicle density is reduced in affected newborns after 1-5 ug/ml doxycycline treatment during gestation
|
|
• hyperkeratosis and other abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
• with reintroduction of doxycycline at >5 ug/ml in diet, hyperkeratotic phenotype is reversed
|
|
• dermal layer in affected double-transgenic newborns is hypervascular after 1-5 ug/ml doxycycline treatment during gestation
|
|
• significant thickening is observed in weanlings treated by doxycycline withdrawal
|
|
• affected double-transgenic newborns after 1-5 ug/ml doxycycline treatment during gestation have reduced number of cornified layers
|
|
• weanlings treated by doxycycline withdrawal develop hyperkeratosis
|
acanthosis
(
J:70670
)
|
• epidermis of affected mice (weanlings treated by doxycycline withdrawal) becomes acanthotic
|
|
• epidermis of affected mice (weanlings treated by doxycycline withdrawal) exhibits hyperplasia
|
|
• epidermis is thinner in affected double-transgenic newborns than single-transgenic pups
|
reddish skin
(
J:70670
)
|
• animals born dead or dying shortly after birth with 1-5 ug/ml doxycycline treatment during gestation have shiny tight erythemic skin
|
shiny skin
(
J:70670
)
tight skin
(
J:70670
)
|
• abnormalities manifest several weeks later than in Tg(tetO-TGFB1*C223S*C225S)1Glk/Tg(KRT5-rtTA)1Glk double-transgenic mice treated with doxycycline
|
|
• weanlings treated by doxycycline withdrawal displays a variable neutrophilic infiltrate characterized by microabcesses within and above cornified layers
|
dermatitis
(
J:70670
)
|
• weanlings treated by doxycycline withdrawal develop dermatitis on scalp and shoulders, as well as ventral surface; dermatitis extends caudally with time
|


Analysis Tools